AZNCF News and Press, AstraZeneca Plc From 02/16/23

Summary The latest inflation numbers from the US at 6.4% YoY show disinflation is ongoing but more Fed rate hikes are likely too, increasing the chances of a recession. The three stocks selected here face lower than average inflation in their sectors, while being potentially insulated f...

Summary AstraZeneca, profit beats expectations. But revenues are down due to lower COVID-19 sales. In 2023, almost zero vaccine intake. However, we are estimating a double-digit revenue growth thanks to Tagrisso, Evusheld, and Lynparza development. AstraZeneca deserves a P/E premium...

Summary Novo Nordisk is a market leader and the only pure-play in the diabetes and obesity care space. The nature of the diabetes care business makes Novo Nordisk rather recession-proof. The stock priced in much of the assumed future growth and I have concerns about competition, esp...

Summary Pharmaceutical major AstraZeneca's stock might have sagged in January, but it got a boost recently after its 2022 earnings release. Revenues and profits have both grown and the company is optimistic about 2023 as well, even though it expects slower growth as COVID-19 treatment s...

The following slide deck was published by AstraZeneca PLC in conjunction with their 2022 Q4 earnings call. For further details see: AstraZeneca PLC 2022 Q4 - Results - Earnings Call Presentation

AstraZeneca PLC (AZN) Q4 2022 Earnings Conference Call February 9, 2023 06:45 ET Company Participants Andy Barnett - Head of Investor Relations Pascal Soriot - Executive Director & Chief Executive Officer Aradhana Sarin - Executive Director & Chief Financial Of...

Summary In this article, I will show you a portfolio that consists of 5 picks that provide you with Dividend Income and Dividend Growth. When allocating $5,000 between 5 stocks, I would not recommend allocating the amount equally due to the higher risks that such an approach brings. ...

Summary Veeva Systems is a cloud-based software solution provider for the pharmaceutical and life sciences industries. Veeva is valued at over $20 billion and is considered a top player in the industry, providing its services to hundreds of pharmaceutical and life sciences companies wor...

Summary According to the financial report of Johnson & Johnson, a partner of AbbVie, sales of Imbruvica decreased in the 4th quarter of 2022 due to increased competition. In less than six months, Humira's biosimilars will go on sale in the United States. Botox Cosmetic sales wer...

Summary FSTX seems undervalued, even at the $7.12 takeover bid. The CFIUS is delaying the closure of the deal, citing review needed to allay US national security concerns. If the deal closes, the stock should rise 30%; if it fails, FSTX still has very valuable assets. The only r...